Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The D-alanyl-D-alanine terminus refers to the C-terminal dipeptide of the pentapeptide stem on the peptidoglycan precursor Lipid II[1][8]. Lipid II is a crucial molecule in bacterial cell wall synthesis, serving as the primary building block for peptidoglycan polymerization and cross-linking[5][6]. The D-Ala-D-Ala motif is highly solvent-accessible and flexible, functioning as the recognition site for bacterial transpeptidase enzymes and as the primary binding site for many antibiotics, notably vancomycin and related glycopeptides[1][2]. Disruption of this motif by drugs effectively halts cell wall assembly, thereby inhibiting bacterial growth and survival[2][8]. Bacterial resistance mechanisms (e.g., D-Ala-D-Lac replacement) exploit this site to evade antibiotic binding[2][8]. This motif does not represent a conventional receptor, enzyme, or transporter, but is nonetheless a validated and essential therapeutic target within bacterial physiology.
Drug binding to D-Ala-D-Ala motif inhibits transpeptidase-mediated crosslinking of peptidoglycan, blocking cell wall synthesis and causing bacteriolysis
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on D-alanyl-D-alanine terminus of Lipid II.